Developing an Anticancer Platinum(II) Compound Based on the Uniqueness of Human Serum Albumin

Zhenlei Zhang; Juzheng Zhang; Tongfu Yang; Shanhe Li; Gang Xu; Hong Liang; Feng Yang

doi:10.1021/acs.jmedchem.3c00001

Developing an Anticancer Platinum(II) Compound Based on the Uniqueness of Human Serum Albumin

J Med Chem. 2023 Apr 27;66(8):5669-5684. doi: 10.1021/acs.jmedchem.3c00001. Epub 2023 Apr 18.

Authors

Zhenlei Zhang¹, Juzheng Zhang¹, Tongfu Yang¹, Shanhe Li¹, Gang Xu¹, Hong Liang¹, Feng Yang¹

Affiliation

¹ State Key Laboratory for Chemistry and Molecular Engineering of Medicinal Resources/Key Laboratory for Chemistry and Molecular Engineering of Medicinal Resources (Ministry of Education of China), Collaborative Innovation Center for Guangxi Ethnic Medicine, School of Chemistry and Pharmaceutical Sciences, Guangxi Normal University, Guilin, Guangxi 541004, P. R. China.

PMID: 37071741
DOI: 10.1021/acs.jmedchem.3c00001

Abstract

To develop the next-generation Pt drug with remarkable activity and low toxicity to maximally inhibit tumor growth, we optimized a Pt(II) thiosemicarbazone compound (C4) with remarkable cytotoxicity to SK-N-MC cells and then constructed a new human serum albumin-C4 (HSA-C4) complex delivery system. The in vivo results showed that C4 and the HSA-C4 complex have remarkable therapeutic efficiency and almost no toxicity; they induced apoptosis and inhibited tumor angiogenesis. This system showed potential as a practical Pt drug. This study could pave the way for developing next-generation dual-targeted Pt drugs and achieving their targeting therapy for cancer.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Antineoplastic Agents* / pharmacology
Cell Line, Tumor
Drug Delivery Systems / methods
Humans
Neoplasms* / drug therapy
Platinum
Serum Albumin, Human

Substances

Serum Albumin, Human
Platinum
Antineoplastic Agents